Ovarian Cancer Trial, Recruiting NCT05457595 Sponsor: CNAO National Center of Oncological Hadrontherapy Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Recruiting

NCT05457595
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People whose general health and ability to carry out daily activities meets a certain minimum level, as measured by a standard medical scale called the Karnofsky Index (score of 70 or above — confirm with trial site what this means for a specific situation)
  • People who have been diagnosed with a return of cancer in the pelvis or groin area, confirmed either by tissue sample or medical imaging
  • People for whom major surgery is not a safe or suitable option
  • People whose cancer has not spread to other parts of the body, or where any known spread has been stable for at least 6 months
  • People who have previously received radiation therapy to the pelvic area
  • People whose tumour is at least 10mm away from the nearby small intestine, as measured on medical imaging — OR people for whom a small surgical procedure to move the intestine away from the tumour area is possible
  • If a spacer (a small device or tissue used to create distance between the tumour and nearby organs) is needed, it must be made from a non-dissolving, body-compatible material such as silicone, Gore-Tex, or natural tissue like fat or muscle
  • People whose medical imaging files from their previous radiation treatment are available in a standard digital format (DICOM)
  • People who are able to understand the nature and consequences of the trial and provide written agreement to participate

Who may not be able to join:

  • People who have a hip replacement, metal implants, or any other condition that would interfere with the medical imaging needed to plan treatment
  • People whose cancer has grown into the intestinal wall
  • People whose cancer has grown into the bladder
  • People whose cancer has grown into nearby blood vessels
  • People who have previously been treated with a type of drug that targets blood vessel growth (anti-angiogenic drugs)
  • People who have a mental health condition or other disorder that would prevent them from being able to give informed consent
  • People who have had a separate, different cancer in the past, unless it was a non-melanoma skin cancer — or unless they have been completely free of that cancer for at least 3 years
  • People who would require a spacer made from dissolving (absorbable) material, such as Vicryl
  • People whose tumour is less than 10mm away from the nearby small intestine on imaging, AND for whom a procedure to create more distance is not possible
  • People for whom an MRI scan cannot be performed or assessed

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Amelia Barcellini, MD, CNAO National Center of Oncological Hadrontherapy

Phone: 390382075501

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
CNAO National Center of Oncological Hadrontherapy
Registry
ClinicalTrials.gov
Start date
24 February 2021
Est. completion
24 February 2028

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

local control; complete response; partial response; stable disease; progression disease

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov